MedTrace Logo

Phase 2A/B Efficacy and Safety of Dabogratinib in Participants With Low Grade Upper Tract Urothelial Carcinoma

NCT07265947 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 230

Last updated 2026-05-13

No results posted yet for this study

Summary

A Phase 2A/B study of Dabogratinib (TYRA-300) in Low Grade Upper Tract Urothelial Carcinoma

Conditions

  • Low Grade Upper Tract Urothelial Carcinoma

Interventions

DRUG

Dabogratinib (TYRA-300) 60mg

Self-administered 60mg dose Oral tablet(s) given daily

DRUG

Dabogratinib (TYRA-300) 80mg

Self-administered 80mg dose Oral tablet(s) given daily

DRUG

Dabogratinib (TYRA-300) TBD

To be determined: Self-administered Oral tablet(s) given daily

Sponsors & Collaborators

  • Tyra Biosciences, Inc

    lead INDUSTRY

Principal Investigators

  • Erik T. Goluboff, MD, MBA · Tyra Biosciences, Inc

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-12-22
Primary Completion
2030-10-31
Completion
2030-11-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07265947 on ClinicalTrials.gov